Full-Time
Quality Control Inspector 1
Cooper Companies
201-500 employees
Global medical devices and vision care
No salary listed
Missouri City, TX, USA
In Person
On-site in Stafford, TX with 5-10% travel.
Bachelor's
 Manufacturing Quality & Test (1) |
|---|
Get referred to Cooper Companies
See people who can refer or advise you
- 0+ years in medical device/healthcare manufacturing or quality inspection experience in an FDA-regulated environment
- High School Diploma or GED required
- Must be proficient in Microsoft Excel, Microsoft Word, Microsoft Teams, Outlook, and PowerPoint
- Ability to read, interpret and execute work Instructions and procedures
- Ability to use inspection tools (calipers, micrometers, gauges or vision systems)
- Strong attention to detail and accuracy
- Strong organizational, interpersonal, verbal, and written communication skills
- Basic understanding of Quality Standard
- Problem-solving mindset
- Travel 5-10%
- Perform routine and detailed inspections of incoming materials, in-process goods, and finished products
- Conduct visual, dimensional, mechanical, and functional inspection using approved methods, tools, and equipment
- Ensure components, subassemblies, and finished products comply with approved company drawings and specifications
- Document inspection results to ensure full traceability
- Identify, document, and report defects or nonconformances (NCMRs)
- Support Site Quality Management in determining disposition of product (accept, reject, rework, return to vendor) in accordance with approved company procedures
- Collaborate cross-functionally to assist with investigations and resolve potential quality issues
- Support corrective and preventive action (CAPA) activities
- Participate in internal and external audits and inspections as required
- Participate in other projects as required by Quality Management
- Perform other duties as assigned
- ASQ Certification (Certified Quality Inspector or Certified Quality Technician) preferred but not required
Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.
Company Size
201-500
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
1958
Get referred to Cooper Companies
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 9, 2026 guidance raised fiscal 2026 revenue to $4.229-$4.252 billion.
- MyDay MiSight and clariti launches are expanding across Japan, EMEA, and APAC.
- Free cash flow reached $273 million in Q3 fiscal 2026, supporting $1 billion buybacks.
What critics are saying
- CooperSurgical's 2023 embryo-media recall triggered $271.6 million charges and 140-plus lawsuits.
- CooperVision's U.S. channel inventory reductions flattened Q3 revenue and cut fiscal guidance.
- Persistent IVF safety concerns can permanently damage CooperSurgical's franchise with fertility clinics.
What makes Cooper Companies unique
- CooperVision's MyDay daily silicone hydrogel portfolio drives premium contact-lens share globally.
- CooperSurgical spans fertility, genomics, and women’s health, covering the reproductive-care workflow.
- Cooper sells in 130-plus countries, pairing global distribution with vertically integrated manufacturing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Performance Bonus
Health Insurance
401(k) Retirement Plan
Life Insurance
Wellness Program
Professional Development Budget
Company News
CooperCompanies reported first-quarter revenues of $1.08 billion, up 7.9% year-on-year and exceeding analyst expectations by 2.7%. The medical device manufacturer, which focuses on vision care contact lenses and women's health products, also beat earnings per share estimates. The result came as the medical devices and supplies sector reported a strong quarter overall. Five tracked companies in the diversified category beat consensus revenue estimates by 2.9% on average, though next quarter's guidance came in 2.2% below expectations. Despite delivering the weakest full-year guidance update in the group, CooperCompanies' shares have risen 9% since reporting. The stock currently trades at $67.62.
Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.
CooperCompanies reported second-quarter revenue of $1.07 billion, missing analyst estimates of $1.10 billion. The medical device company's sales were flat year-on-year, whilst its operating margin improved to 20.8% from 16.6% in the same quarter last year. The company lowered its full-year revenue guidance to $4.24 billion at the midpoint, down from $4.30 billion, representing a 1.5% decrease. Adjusted earnings per share guidance was also reduced to $4.53 at the midpoint, a 1.9% decrease. Despite beating analyst expectations with adjusted EPS of $1.15 versus estimates of $1.12, the company's shares fell 16.8% following the announcement. CEO Al White cited reduced US channel inventory at CooperVision as weighing on results. CooperCompanies develops medical devices for vision care and women's health.
CooperCompanies reported third quarter fiscal 2026 revenue of $1.066 billion, up 1% year-over-year. The medical device company posted GAAP diluted earnings per share of $2.24, compared with $0.49 in the prior year quarter, primarily driven by a $307.2 million discrete tax benefit from a favourable UK tax examination completion. Non-GAAP diluted EPS reached $1.15, up 4% from last year. Free cash flow increased 66% to $273.0 million. The company repurchased $339.1 million of common stock during the quarter. CooperVision revenue was flat at $717.0 million, whilst CooperSurgical revenue rose 2% to $349.2 million, with 6% fertility growth. The company cited reduced US channel inventory at CooperVision impacting results. CooperCompanies updated its fiscal 2026 guidance, projecting total revenue of $4.229-$4.252 billion and non-GAAP diluted EPS of $4.51-$4.55.
The Cooper Companies reported total revenue of $1.08 billion for the quarter ending April 2026, up 7.9% year over year. International markets contributed significantly to this performance, with EMEA generating $289.7 million (26.8% of total revenue) and Asia Pacific adding $130.6 million (12.1%). EMEA revenue exceeded Wall Street expectations by 5.18%, whilst Asia Pacific fell marginally short by 0.17%. The surgical and contact lens products maker's EMEA performance represented growth from $248.6 million in the year-ago quarter, though Asia Pacific revenue declined from $138.6 million over the same period. For the current fiscal quarter, analysts project total revenue of $1.12 billion, with EMEA expected to contribute $305.46 million and Asia Pacific $143.73 million.